Vital discontinues ELAD system after Phase III miss

Vital Therapies Inc. (NASDAQ:VTL) said it will discontinue development of its ELAD system and explore strategic options. The move comes after newly released

Read the full 236 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE